AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
On April 18, the United States Senate turned back, at least for the present, the looming danger that older Americans will be denied the right, if they choose, to spend their own money to get lifesaving innovative drugs under Medicare. An effort to cut off a pro-life filibuster, which was being led by Sen. Charles Grassley (R-Ia.), fell short of the 60 votes required for "cloture," which would have brought S.3 up for a vote.
Proposed by Senate Finance Committee Chairman Max Baucus (D.-Mt.), S.3 would authorize government price-fixing for prescription drugs under Medicare. The Senate vote followed by several weeks passage by the U.S. House of Representatives of H.R. 4, a similar bill that would have mandated government price-fixing for Medicare prescription drugs.
The National Right to Life Committee has repeatedly warned that such government limits on the right of older people to choose to purchase insurance plans that include new innovative drugs, would deny access to lifesaving medications to millions of senior citizens.
Similar price-fixing actions in the Department of Veterans Affairs' health care system have already denied veterans subject to it access to 81% of drugs approved by the Food and Drug Administration since 2000. (See page one of the March and April issues of NRL News.)
However, the battle is far from over. Following the unsuccessful cloture vote, Senator Ron ...